FDA Approves Onglyza for Type 2 Diabetes

The Food and Drug Administration approved Friday the use of Onglyza, a once-daily treatment for type two diabetes, reported WebMD. Onglyza, made by Bristol-Myers Squibb and distributed by Bristol-Myers Squibb and AstraZeneca Pharmaceuticals, is a DPP-4 inhibitor, which blocks enzymes that degrade GLP-1, a hormone that lowers a patient’s blood sugar by stimulating the pancreas to release